Tokyo Tape
Sign in
← Trans Genic

Quarterly report · Q3

2342.TEDINET S100STDC
Period2023-04-01 → 2023-12-31
Filed2024-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥9.7bn2023-04-01 → 2023-12-31Cons.Net sales
Revenue¥11.4bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥8.5bn2022-04-01 → 2022-12-31Cons.Net sales
Operating income¥52m2023-04-01 → 2023-12-31Cons.Operating income
Operating income¥153m2022-04-01 → 2022-12-31Cons.Operating income
Ordinary income¥51m2023-04-01 → 2023-12-31Cons.Ordinary income
Ordinary income¥199m2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥385m2022-04-01 → 2022-12-31Cons.Ordinary income
Profit before tax¥7m2023-04-01 → 2023-12-31Cons.Income before income taxes
Profit before tax¥344m2022-04-01 → 2022-12-31Cons.Income before income taxes
Net income (owners)−¥38m2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥410m2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥182m2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income−¥43m2023-04-01 → 2023-12-31Cons.Profit loss
Net income¥171m2022-04-01 → 2022-12-31Cons.Profit loss
Total assets¥10.4bnat 2023-12-31Cons.Assets
Total assets¥10.7bnat 2023-03-31Cons.Assets
Total assets¥10.9bnat 2022-12-31Cons.Total assets (5-year summary)
Total liabilities¥4.4bnat 2023-12-31Cons.Liabilities
Total liabilities¥4.6bnat 2023-03-31Cons.Liabilities
Net assets / equity¥6.0bnat 2023-12-31Cons.Net assets
Net assets / equity¥6.1bnat 2023-03-31Cons.Net assets
Net assets / equity¥6.7bnat 2022-12-31Cons.Net assets (5-year summary)
Cash and deposits¥2.8bnat 2023-12-31Cons.Cash and deposits
Cash and deposits¥3.5bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥-2.272023-04-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-5.152023-10-01 → 2023-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-24.322022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥10.812022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥7.542022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio56.7%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio56.4%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio60.4%at 2022-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 32
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-12-31−¥5m
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2023-12-31¥450,000
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-12-31−¥5m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31−¥152m
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥1.6bn
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥1.6bn
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥5m
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2023-04-01 → 2023-12-31−¥109m
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥8.1bn
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥8.1bn
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥760,000
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥313m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-12-31¥9.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-12-31¥9.7bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-12-31¥5m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-12-31¥204m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥4m
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-12-31¥2m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥6m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥157m
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥1.8bn
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥1.8bn
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥5m
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥132m
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥6.7bn
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥6.7bn
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥1m
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥179m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥8.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥8.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥6m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥310m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 361
ItemContextValueUnit
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember178753000JPY
Operating incomePrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember310370000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember-157065000JPY
Operating incomePrior1YTDDuration153305000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember1630949000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember8111606000JPY
Revenues from external customersCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember9742555000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember450000JPY
Revenues from external customersCurrentYTDDuration9743005000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember4500000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember760000JPY
Transactions with other segmentsCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember5260000JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember-5260000JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember1635449000JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember8112366000JPY
Net salesCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember9747816000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember-4810000JPY
Net salesCurrentYTDDuration9743005000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q3r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember-109342000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q3r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember313347000JPY
Operating incomeCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember204005000JPY
Operating incomeCurrentYTDDuration_ReconcilingItemsMember-151741000JPY
Operating incomeCurrentYTDDuration52263000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)福岡財務支局長
Filing date cover pageFilingDateInstant2024-02-13
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第26期第３四半期（自　2023年10月１日　至　2023年12月31日）
Company name cover pageFilingDateInstant
Original text (Japanese)株式会社トランスジェニック
Company name in english cover pageFilingDateInstantTRANS GENIC INC.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　福永　健司
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)福岡県福岡市中央区天神二丁目３番36号
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)(092)288－8470（代表）
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)取締役　経理財務部長　　渡部　一夫
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)福岡県福岡市中央区天神二丁目３番36号
Telephone number nearest place of contact cover pageFilingDateInstant(092)288－8470
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)取締役　経理財務部長　　渡部　一夫
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE05317
Fund codeFilingDateInstant－
Security codeFilingDateInstant23420
Filer name in japaneseFilingDateInstant
Original text (Japanese)株式会社トランスジェニック
Filer name in englishFilingDateInstantTRANS GENIC INC.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第四号の三様式
Accounting standardsFilingDateInstantJapan GAAP
Whether consolidated financial statements are preparedFilingDateInstanttrue

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass